B-
BiotechTV - News
Jefferies London 2026: Intellia is currently in front of FDA for the potential approval of the first in vivo (in the body) CRISPR gene editing therapy - it is for hereditary angioedema
0:00-9:34
President & CEO John Leonard discusses the program and compares and contrasts it to more traditional medicines. He also provides an update on the company's transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) program.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/Jefferies-London-2026-Intellia-is-currently-in-front-of-FDA-for-the-potential-approval-of-the-first-in-vivo-in-the-body-CRISPR-gene-editing-therapy---it-is-for-hereditary-angioedema-e3sg7dr
Published
November 16, 2026
Duration
10 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#potentialapproval #crisprgeneediting #hereditaryangioedema #lifesciences
